The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists

Journal of Nephrology

Volumn 28, Issue 4, 2015, Pages 393-402

  Coppolino, Giuseppe ^a   Simeoni, Mariadelina ^a   Summaria, Chiara ^a   Postorino, Maria Concetta ^a   Rivoli, Laura ^a   Strazzulla, Alessio ^a   Torti, Carlo ^a   Fuiano, Giorgio ^a  

^a University Hospital Magna Graecia   (Italy)

Author keywords

Chronic kidney disease; Haemodialysis; Peritoneal dialysis; Renal disease; Renal failure; Renal transplant; Tenofovir; Tenofovir disoproxil

Indexed keywords

ADEFOVIR; EMTRICITABINE; ENTECAVIR; HEPATITIS B CORE ANTIGEN; IMMUNOGLOBULIN M; INTERFERON; LAMIVUDINE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; TELBIVUDINE; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; ANTIVIRUS AGENT; TENOFOVIR;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS B; HEMODIALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOLOGICAL TOLERANCE; KIDNEY CLEARANCE; KIDNEY INJURY; KIDNEY METABOLISM; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; VIRUS REPLICATION; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; GROWTH, DEVELOPMENT AND AGING; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; KIDNEY; PATHOPHYSIOLOGY; PATIENT SAFETY; RISK ASSESSMENT; TREATMENT OUTCOME; URINARY EXCRETION;

ANTIVIRAL AGENTS; GLOMERULAR FILTRATION RATE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KIDNEY; PATIENT SAFETY; RENAL ELIMINATION; RISK ASSESSMENT; TENOFOVIR; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 84937442352     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-015-0214-0     Document Type: Review

References (77)

1. Repp R, Rhiel S, Heermann KH, Schaefer S, Keller C, Ndumbe P, Lampert F, Gerlich WH (1993) Genotyping by multiplex polymerase chain reaction for detection of endemic hepatitis B virus transmission. J Clin Microbiol 31(5):1095–1102
2. Uhl P, Fricker G, Haberkorn U, Mier W (2014) Current status in the therapy of liver diseases. Int J Mol Sci 15(5):7500–7512
3. Maynard JE, Hepatitis B (1990) Global importance and need for control. Vaccine 8 Suppl:S18–S20 (discussion S21–S13)
4. European Association For The Study of The Liver (2012) EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57(1):167–185
5. WHO (2013) Global policy report on the prevention and control of viral hepatitis
6. WHO (2009) Weekly epidemiological record. pp 405–420
7. Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN, Mares A, Miller JK, Moyer LA (1990) The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 263(9):1218–1222
8. WHO (2015) Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
9. Jenh AM, Thio CL, Pham PA (2009) Tenofovir for the treatment of hepatitis B virus. Pharmacotherapy 29(10):1212–1227
10. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA et al (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365(9454):123–129
11. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B et al (2014) Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 146(4):980–988
12. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G et al (2005) A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129(2):528–536
13. Marcellin P, Buti M, Krastev Z, de Man RA, Zeuzem S, Lou L, Gaggar A, Flaherty JF, Massetto B, Lin L et al (2014) Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J Hepatol 61(6):1228–1237
14. Pipili C, Cholongitas E, Papatheodoridis G (2014) Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther 39(1):35–46
15. Berg T, Zoulim F, Moeller B, Trinh H, Marcellin P, Chan S, Kitrinos KM, Dinh P, Flaherty JF Jr, McHutchison JG et al (2014) Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol 60(4):715–722
16. Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, Chan S, Suarez E, Lavocat F, Snow-Lampart A, Frederick D et al (2010) Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 139(4):1207–1217
17. Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S (2012) Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol 10(8):941–946 (quiz e968)
18. Gallant JE, Deresinski S (2003) Tenofovir disoproxil fumarate. Clin Infect Dis 37(7):944–950
19. Hostetler KY (2009) Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 82(2):A84–A98
20. Markowitz M, Zolopa A, Squires K, Ruane P, Coakley D, Kearney B, Zhong L, Wulfsohn M, Miller MD, Lee WA (2014) Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, HIV-infected adults. J Antimicrob Chemother 69(5):1362–1369
21. Birkus G, Hitchcock MJ, Cihlar T (2002) Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46(3):716–723
22. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S et al (2008) Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 197(1):102–108
23. Bam RA, Yant SR, Cihlar T (2014) Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther 19:687–692
24. Cihlar T, Ho ES, Lin DC, Mulato AS (2001) Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20(4–7):641–648
25. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD, Wieman LM, Eisenberg EJ, Rhodes GR (2006) Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 50(10):3297–3304
26. Rodriguez-Novoa S, Alvarez E, Labarga P, Soriano V (2010) Renal toxicity associated with tenofovir use. Expert opinion on drug safety 9(4):545–559
27. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Nino MD, Izquierdo MC, Poveda J, Sainz-Prestel V, Ortiz-Martin N, Parra-Rodriguez A, Selgas R et al (2011) Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011:354908
28. Perazella MA (2010) Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. Kidney Int 78(11):1060–1063
29. Tourret J, Deray G, Isnard-Bagnis C (2013) Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol 24(10):1519–1527
30. van Bommel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Huppe D, Stein K, Trojan J et al (2010) Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51(1):73–80
31. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N et al (2010) Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51(2):422–430
32. Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, Borroto-Esoda K, Miller MD (2014) No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 59(2):434–442
33. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA et al (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381(9865):468–475
34. Tujios SR, Lee WM (2013) Update in the management of chronic hepatitis B. Curr Opin Gastroenterol 29(3):250–256
35. HBV Natural History and Outcomes (2013). Hepatology 58(S1):626A–647A. doi:10.1002/hep.26855
36. Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF (2006) Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Clin Pharmacokinet 45(11):1115–1124
37. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D’Agati VD, Markowitz GS (2010) Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 78(11):1171–1177
38. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, Edwards SG, Johnson MA, Connolly JO (2009) Tenofovir-associated renal and bone toxicity. HIV Med 10(8):482–487
39. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD et al (2010) Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 24(11):1667–1678
40. Ando M, Tsuchiya K, Nitta K (2012) How to manage HIV-infected patients with chronic kidney disease in the HAART era. Clin Exp Nephrol 16(3):363–372
41. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, Legendre C, Martinez F, Molina JM (2003) Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 36(8):1070–1073
42. Brennan A, Evans D, Maskew M, Naicker S, Ive P, Sanne I, Maotoe T, Fox M (2011) Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS 25(13):1603–1609
43. Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O et al (2013) Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A: D study. J Infect Dis 207(9):1359–1369
44. Wikman P, Safont P, Del Palacio M, Moreno A, Moreno S, Casado JL (2013) The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients. Nephrol Dial Transplant 28(8):2073–2081
45. Brancaccio G, Nardi A, Giuberti TG, Andreone P, Angarano G, Fasano M, Levantesi F, Verucchi G, Fattovich G, Massari M, Maimone S, Contini C, Gavrila C, Gaeta GB (2013) Changing the face of hepatitis B. In: Final report of the Italian Master-B cohort, vol 58. Hepatology 637A
46. Ha NB, Ku K, Ha NB et al (2013) Renal function in chronic hepatitis B (CHB) patients treated with tenofovir dipivoxil fumarate (TDF) monotherapy—a matched case cohort study. In: Digestive disease week. Orlando
47. Gara N, Zhao X, Collins MT, Chong WH, Kleiner DE, Jake Liang T, Ghany MG, Hoofnagle JH (2012) Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 35(11):1317–1325
48. Pipili CL, Papatheodoridis GV, Cholongitas EC (2013) Treatment of hepatitis B in patients with chronic kidney disease. Kidney Int 84(5):880–885
49. Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, Flaherty J, Dinh P, Rossi S, Subramanian GM et al (2013) Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl 19(6):594–601
50. Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D, Lovegren M, Cohen D et al (2012) Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 143(3):619 e611–628 e611
51. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, Horban A, Wang C, Kwan P et al (2011) Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 53(1):62–72
52. Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, Flaherty JF, Lin L, Corsa A et al (2014) Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology 146(5):1240–1248
53. Winston J, Deray G, Hawkins T, Szczech L, Wyatt C, Young B (2008) Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis 47(11):1449–1457
54. Fontana RJ (2009) Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 49(5 Suppl):S185–S195
55. Duarte-Rojo A, Heathcote EJ (2010) Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. Therap Adv Gastroenterol 3(2):107–119
56. Bam RA, Birkus G, Babusis D, Cihlar T, Yant SR (2014) Metabolism and antiretroviral activity of tenofovir alafenamide in CD4(+) T-cells and macrophages from demographically diverse donors. Antivir Ther 19:669–677
57. Sax PE, Zolopa A, Brar I, Elion R, Ortiz R, Post F, Wang H, Callebaut C, Martin H, Fordyce MW et al (2014) Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 Study. J Acquir Immune Defic Syndr 67:52–58
58. Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, Lawson E, Zhao S, Subramanian GM et al (2015) Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol 62(3):533–540
59. Buti M, Fung S, Gane E, Afdhal NH, Flisiak R, Gurel S, Flaherty JF, Martins EB, Yee LJ, Dinh P et al (2015) Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hep Intl 9(2):243–250
60. Yap DY, Chan TM (2014) Evolution of hepatitis B management in kidney transplantation. World J Gastroenterol 20(2):468–474
61. Daude M, Rostaing L, Saune K, Lavayssiere L, Basse G, Esposito L, Guitard J, Izopet J, Alric L, Kamar N (2011) Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients. Transplantation 91(8):916–920
62. Froio N, Nicastri E, Comandini UV, Cherubini C, Felicioni R, Solmone M, Di Giulio S, Petrosillo N (2003) Contamination by hepatitis B and C viruses in the dialysis setting. Am J Kidney Dis 42(3):546–550
63. Di Biagio A, Bassetti M, Briozzo A, Ferrazin A, Rosso R, Gatti G, Cruciani M, Bassetti D (2004) Tenofovir use in a patient with a severe renal impairment. HIV medicine 5(6):450–451
64. Pipili C, Cholongitas E (2014) Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation. World J Hepatol 6(5):315–325
65. Hall AM, Hendry BM, Nitsch D, Connolly JO (2011) Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 57(5):773–780
66. Viganò M (2013) LP: Hepatitis B virus treatment: which patients should be treated with nucleo(t)side analogue? In: Clinical liver disease, vol 2. pp 21–23
67. Campbell LJ, Dew T, Salota R, Cheserem E, Hamzah L, Ibrahim F, Sarafidis PA, Moniz CF, Hendry BM, Poulton M et al (2012) Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients. BMC Nephrol 13:85
68. Rasmussen TA, Jensen D, Tolstrup M, Nielsen US, Erlandsen EJ, Birn H, Østergaard L, Langdahl BL, Laursen AL (2012) Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One 7(3):e32445
69. Allavena C, Bach-Ngohou K, Billaud E, Sécher S, Dejoie T, Reliquet V, Fakhouri F, Raffi F (2013) Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine + nevirapine regimen. J Antimicrob Chemother 68(12):2866–2870
70. Oboho I, Abraham AG, Benning L, Anastos K, Sharma A, Young M, Burian P, Gandhi M, Cohen M, Szczech L (2013) Tenofovir use and urinary biomarkers among HIV-infected women in the Women’s Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 62(4):388–395
71. Bolignano D, Coppolino G, Aloisi C, Romeo A, Nicocia G, Buemi M (2008) Effect of a single intravenous immunoglobulin infusion on neutrophil gelatinase-associated lipocalin levels in proteinuric patients with normal renal function. J Investig Med 56(8):997–1003
72. Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, Zhong L, Ramanathan S, Rhee MS, Fordyce MW et al (2013) Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr 63(4):449–455
73. De Clercq E (2013) A cutting-edge view on the current state of antiviral drug development. Med Res Rev. doi:10.1002/med.21281
74. Kim YJ, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH (2012) Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. World J Gastroenterol 18(47):6996–7002
75. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A (2011) Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 53(3):774–780
76. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S et al (2011) Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 60(2):247–254
77. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K et al (2011) Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140(1):132–143